Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
08 janv. 2024 09h45 HE
|
Curative Biotechnology, Inc.
Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Curative...
[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
24 nov. 2021 15h05 HE
|
Curative Biotechnology, Inc.
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
24 nov. 2021 10h00 HE
|
Curative Biotechnology, Inc.
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE
07 oct. 2021 10h20 HE
|
Curative Biotechnology, Inc.
License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies Boca Raton, FL, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Curative...
Curative Biotechnology, Inc. Files 2021 First Quarter Financials and Issues Letter to Shareholders
25 mai 2021 09h50 HE
|
Curative Biotechnology, Inc.
Boca Raton, FL, May 25, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company targeting novel treatments for...
Connectyx Technologies Issues Shareholder Update
01 mai 2020 09h30 HE
|
Connectyx Technologies Holdings Group, Inc
BOCA RATON, FL, May 01, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC PINK: CTYX), a global biomedical company issues the following update to shareholders. Dear...